Wedbush starts RNA-focused standout Wave Life Sciences with an Outperform

As previously reported, Wedbush initiated coverage of Wave Life Sciences (WVE) with an Outperform rating and $18 price target Wave stands out from all other RNA-focused peers as its four clinical programs across three different modalities have all reported positive clinical or preclinical data, notes the analyst, who also sees the company having established accelerated approval pathway in two indications. The current programs validate the PRISM platform to further explore additional indications, so the firm sees “strong potential in Wave’s robust yet still growing pipeline,” the analyst added.